An Alternative Splice Form of Mdm2 Induces p53-independent Cell Growth and Tumorigenesis
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The Mdm2 gene is amplified in approximately one-third of human sarcomas and overexpressed in a variety of other human cancers. Mdm2 functions as an oncoprotein, in part, by acting as a negative regulator of the p53 tumor suppressor protein. Multiple spliced forms of Mdm2 transcripts have been observed in human tumors; however, the contribution of these variant transcripts to tumorigenesis is unknown. In this report, we isolate alternative splice forms of Mdm2 transcripts from sarcomas that spontaneously arise in Mdm2-overexpressing mice, including Mdm2-b, the splice form most commonly observed in human cancers. Transduction of Mdm2-b into a variety of cell types reveals that Mdm2-b promotes p53-independent cell growth, inhibits apoptosis, and up-regulates the RelA subunit of NFkappaB. Furthermore, expression of Mdm2-b induces tumor formation in transgenic mice. These results identify a p53-independent role for Mdm2 and determine that an alternate spliced form of Mdm2 can contribute to formation of cancer via a p53-independent mechanism. These findings also provide a rationale for the poorer prognosis of those patients presenting with tumors harboring multiple Mdm2 transcripts.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, Mdm2 also has p53-independent activities, and the pathways that mediate these functions are unresolved.”
From Mdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair (2005) · cites this paper as [33]
In the citing paper
“Combined, these reports suggest that Mdm2 has functions independent of p53 that contribute to transformation.”
From Mdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair (2005) · cites this paper as [33]
Citations
Cites
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Self-citationMomand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Wang, C.-Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., & Baldwin, A. S. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,711
NF-κB in cancer: from innocent bystander to major culprit
Karin, M., Cao, Y., Greten, F. R., & Li, Z.-W. (2002) · Nature Reviews Cancer · doi:10.1038/nrc780 · Cited by 2,478
Gewirtz, D. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00307-4 · Cited by 2,240
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,451
Research works printed but not linked: 7
- Finlay, 1993, Mol. Cell. Biol., 13, 301
- Chen, 1993, Mol. Cell. Biol., 13, 4107
- Reifenberger, 1993, Cancer Res., 53, 2736
- Cordon-Cardo, 1994, Cancer Res., 54, 794
- Yam, 1999, Cancer Res., 59, 5075
- Matsumoto, 1998, Cancer Res., 58, 609
- Dang, 2002, Cancer Res., 62, 1222
Cited by
The gene encoding the splicing factor SF2/ASF is a proto-oncogene
Karni, R., de Stanchina, E., Lowe, S. W., Sinha, R., Mu, D., & Krainer, A. R. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1209 · Cited by 934
“Many other genes that are involved in proliferation and invasiveness are alternatively spliced, and specific isoforms that contribute to the transformed phenotype are frequently elevated in tumor”
BackgroundThe Mdm2–p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor
Manfredi, J. J. (2010) · Genes & Development · doi:10.1101/gad.1941710 · Cited by 344
“Although full-length Mdm2 was used for expression in certain transgenic models, examination of Mdm2 in resulting tumors showed that the Mdm2 can be truncated (Steinman et al. 2004).”
BackgroundThe Roles of MDM2 and MDMX in Cancer
Karni-Schmidt, O., Lokshin, M., & Prives, C. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040349 · Cited by 296
Alternative splicing: an emerging topic in molecular and clinical oncology
Pajares, M. J., Ezponda, T., Catena, R., Calvo, A., Pio, R., & Montuenga, L. M. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70104-3 · Cited by 267
Tisato, V., Voltan, R., Gonelli, A., Secchiero, P., & Zauli, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0500-5 · Cited by 256
MDM2 Promotes Cell Motility and Invasiveness by Regulating E-Cadherin Degradation
Yang, J.-Y., Zong, C. S., Xia, W., Wei, Y., Ali-Seyed, M., Li, Z., Broglio, K., Berry, D. A., & Hung, M.-C. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00172-06 · Cited by 211
Alterations of pre‐mRNA splicing in cancer
Kalnin̨a, Z., Zayakin, P., Silin̨a, K., & Linē, A. (2005) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20156 · Cited by 196
“Thus, for example, MDM2-b, one of the splice forms lacking a TP53-binding domain has been shown to promote TP53-independent cell growth, to inhibit apoptosis, and to up-regulate the RelA subunit of NFkappaB (Steinman et al., 2004).”
BackgroundGiant cell tumor of bone: A basic science perspective
Cowan, R. W., & Singh, G. (2013) · Bone · doi:10.1016/j.bone.2012.10.002 · Cited by 158
“express an alternatively-spliced MDM2 variant [56] that may promote neoplastic growth in a p53-independent manner [60].”
BackgroundStabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway
Zhang, Z., Wang, H., Li, M., Rayburn, E. R., Agrawal, S., & Zhang, R. (2005) · Oncogene · doi:10.1038/sj.onc.1208814 · Cited by 162
“Some of these variants transform NIH3T3 cells and are associated with high-grade and late-stage human cancers (Liang et al., 2004; Steinman et al., 2004).”
BackgroundMdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair
Alt, J. R., Bouska, A., Fernandez, M. R., Cerny, R. L., Xiao, H., & Eischen, C. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413387200 · Cited by 131
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
Yuan, Y., Liao, Y.-M., Hsueh, C.-T., & Mirshahidi, H. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-16 · Cited by 132
“Additionally, MDM2 can cause carcinogenesis independent of p53 pathway [ 8 ].”
Mnk2 Alternative Splicing Modulates the p38-MAPK Pathway and Impacts Ras-Induced Transformation
Maimon, A., Mogilevsky, M., Shilo, A., Golan‐Gerstl, R., Obiedat, A., Ben-Hur, V., Lebenthal-Loinger, I., Stein, I., Reich, R., Beenstock, J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.041 · Cited by 121
“Several examples of such regulation of important tumor suppressors already exist: BIN1, MDM2, Caspase-9, BCL-2 family members, and others (Bae et al., 2000; Ge et al., 1999; Hossini et al., 2006; Kim et al., 2008; Srinivasula et al., 1999; Steinman et al., 2004).”
BackgroundSpliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis
Zheng, T., Wang, J., Zhao, Y., Zhang, C., Lin, M., Wang, X., Yu, H., Liu, L., Feng, Z., & Hu, W. (2013) · Nature Communications · doi:10.1038/ncomms3996 · Cited by 108
Xi, L., Feber, A., Gupta, V., Wu, M., Bergemann, A. D., Landreneau, R. J., Litle, V. R., Pennathur, A., Luketich, J. D., & Godfrey, T. E. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn697 · Cited by 107
Chandler, D. S., Singh, R. K., Caldwell, L. C., Bitler, J. L., & Lozano, G. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4271 · Cited by 105
“Furthermore, expression of a mouse alternative spliced form analogous to MDM2 can lead to the formation of myeloid sarcomas in transgenic mouse studies (22).”
BackgroundDelineation of TMPRSS2-ERG Splice Variants in Prostate Cancer
Hu, Y., Dobi, A., Sreenath, T., Cook, C., Tadase, A. Y., Ravindranath, L., Cullen, J. C., Furusato, B., Chen, Y., Thangapazham, R. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0531 · Cited by 99
Rogulski, K. R., Li, Y., Rothermund, K. D., Pu, L., Watkins, S. C., Yi, F., & Prochownik, E. V. (2005) · Oncogene · doi:10.1038/sj.onc.1208897 · Cited by 103
“Owing to its capacity to abrogate the antiproliferative effects of p53, Mdm2 overexpression is transforming (Ganguli et al., 2000; Moore et al., 2003; Steinman et al., 2004).”
BackgroundVisvanathan, A., Patil, V., Abdulla, S., Hoheisel, J. D., & Somasundaram, K. (2019) · Genes · doi:10.3390/genes10020141 · Cited by 96
“Stainmanetal showed that the MDM2-bvariant induces tumor formation, activates NFκB and inhibits apoptosis in a p53-independent manner [59].”
BackgroundThe master regulator FUBP1: its emerging role in normal cell function and malignant development
Debaize, L., & Troadec, M. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2933-6 · Cited by 90
Dysregulation of ubiquitin ligases in cancer
Qi, J., & Ronai, Z. A. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.09.001 · Cited by 73
MDM2 Polymorphism, Survival, and Histology in Early-Stage Non–Small-Cell Lung Cancer
Heist, R. S., Zhou, W., Chirieac, L. R., Cogan-Drew, T., Liu, G., Su, L., Neuberg, D. S., Lynch, T. J., Wain, J. C., & Christiani, D. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8914 · Cited by 63
Matijasevic, Z., Steinman, H. A., Hoover, K., & Jones, S. N. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01108-07 · Cited by 58
“The results of experiments in vitro or in vivo involving the forced overexpression of Mdm proteins suggest that Mdm2 and MdmX may also have p53-independent roles in promoting cell growth (13, 23, 29, 38, 41 ).”
BackgroundSelf-citationCancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing
Shkreta, L., Bell, B., Revil, T., Venables, J. P., Prinos, P., Elela, S. A., & Chabot, B. (2013) · Cancer treatment and research · doi:10.1007/978-3-642-31659-3_3 · Cited by 61
Splicing factor SRSF1 negatively regulates alternative splicing of MDM2 under damage
Comiskey, D. F., Jacob, A. G., Singh, R. K., Tapia-Santos, A. S., & Chandler, D. S. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv223 · Cited by 63
“In vivo, the mouse homolog Mdm2-b has been shown to lead to tumorigenesis in a syngeneic mouse model, while an MDM2-ALT1-like protein accelerated lymphomagenesis in E -Myc mice (29,67).”
BackgroundTumor suppression in skin and other tissues via cross-talk between vitamin D- and p53-signaling
Reichrath, J., Reichrath, S., Heyne, K., VOGT, T. M., & Roemer, K. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00166 · Cited by 60
MDM2 Chaperones the p53 Tumor Suppressor
Wawrzynów, B., Żylicz, M., Wallace, M., Hupp, T. R., & Żylicz, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702767200 · Cited by 60
Novel natural product therapeutics targeting both inflammation and cancer
Qin, J., Wang, W., & Zhang, R. (2017) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(17)30062-6 · Cited by 62
“MDM2 directly binds to the first two Sp1-binding sites in the p65 promoter, increases p65 expression, and activates p65-mediated gene expression ([28-29]).”
BackgroundRecent Advances in Validating MDM2 as a Cancer Target
Rayburn, E. R., Ezell, S. J., & Zhang, R. (2009) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152009789124628 · Cited by 54
Pre-mRNA Missplicing as a Cause of Human Disease
Novoyatleva, T., Tang, Y., Rafalska, I., & Stamm, S. (2006) · Progress in molecular and subcellular biology · doi:10.1007/978-3-540-34449-0_2 · Cited by 55
“…obvious mutations Gene Disease Reference Estrogen receptor Breast-cancer Pfeffer et al. (1993) Gris1: Graffi Integration leukemia Denicourt et al. (2003) Site 1 BAFF cancer Gavin et al. (2003) MDM 2 cancer Steinman et al. (2004); Lukas et al. (2001) ADAR inflammation Yang et al. (2003) HOX2.”
Ligand-induced sequestering of branchpoint sequence allows conditional control of splicing
Kim, D.-S., Gusti, V., Dery, K. J., & Gaur, R. K. (2008) · BMC Molecular Biology · doi:10.1186/1471-2199-9-23 · Cited by 51
Ying, M., Zhang, L., Zhou, Q., Shao, X., Cao, J., Zhang, N., Li, W., Zhu, H., Yang, B., & He, Q. (2016) · Oncogene · doi:10.1038/onc.2015.503 · Cited by 44
Aberrant splicing of the DMP1 ‐ ARF ‐ MDM2 ‐p53 pathway in cancer
Inoue, K., & Fry, E. A. (2016) · International Journal of Cancer · doi:10.1002/ijc.30003 · Cited by 43
“demonstrated that MDM2-B promotes tumorigenesis in a transgenic mouse model.(59) Fridman et al.”
BackgroundMDM4 (MDMX) and its Transcript Variants
Mancini, F., Conza, G. D., & Moretti, F. (2009) · Current Genomics · doi:10.2174/138920209787581280 · Cited by 49
“For MDM2 some studies have indeed confirmed such activity in in vivo models [72,73].”
BackgroundThe Splicing Factor FUBP1 Is Required for the Efficient Splicing of Oncogene MDM2 Pre-mRNA
Jacob, A. G., Singh, R. K., Mohammad, F., Bebee, T. W., & Chandler, D. S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.554717 · Cited by 42
Platonova, N., Scotti, M., Babich, P. S., Bertoli, G. R., Mento, E., Meneghini, V., Egeo, A., Zucchi, I., & Merlo, G. R. (2007) · Cell and Tissue Research · doi:10.1007/s00441-006-0364-4 · Cited by 42
“Mdm2 has also been shown to be an effector of p19ARF in the absence of WT p53 (Steinman et al. 2004).”
Splicing Up Mdm2 for Cancer Proteome Diversity
Okoro, D. R., Rosso, M., & Bargonetti, J. (2012) · Genes & Cancer · doi:10.1177/1947601912455323 · Cited by 43
Guidi, C. J., Mudhasani, R., Hoover, K. L., Koff, A., Leav, I., Imbalzano, A. N., & Jones, S. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1451 · Cited by 39
“blasticidin, the cells were harvested and plated in 10-cm dishes, and a proliferation assay was done using the transduced cells (35).”
MethodSelf-citationMdmX regulates transformation and chromosomal stability in p53-deficient cells
Matijasevic, Z., Krzywicka-Racka, A., Sluder, G., & Jones, S. N. (2008) · Cell Cycle · doi:10.4161/cc.7.19.6797 · Cited by 34
Self-citationSharma, S., & Lichtenstein, A. K. (2009) · Blood · doi:10.1182/blood-2009-03-206482 · Cited by 37
Subcellular localization of Mdm2 expression and prognosis of breast cancer
Park, H. S., Park, J. M., Park, S., Cho, J., Kim, S. I., & Park, B. (2013) · International Journal of Clinical Oncology · doi:10.1007/s10147-013-0639-1 · Cited by 35
Okoro, D. R., Arva, N. C., Gao, C., Polotskaia, A., Puente, C., Rosso, M., & Bargonetti, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077643 · Cited by 36
“[33,34], or MDM2-B in mice [35], increases tumor formation in”
BackgroundAlternative Splicing of Pre-mRNA in Cancer
Körner, M., & Miller, L. J. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.081135 · Cited by 38
Hayashida, K., Kajino, K., Hattori, M., Wallace, M., Morrison, I. W., Greene, M. I., & Sugimoto, C. (2012) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2012.08.008 · Cited by 30
Dias, C. S., Liu, Y., Yau, A., Westrick, L., & Evans, S. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3013 · Cited by 34
“Some of these variants show transforming ability (12, 21, 22).”
BackgroundVitamin D directly regulates Mdm2 gene expression in osteoblasts
Chen, H., Reed, G. E., Guardia, J., Lakhan, S., Couture, O. P., Hays, E., & Chandar, N. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.11.003 · Cited by 32
“) involved in different cellular activities such as cell fate determination, differentiation and signaling [4, 5, 6, 7].”
BackgroundThe regulation of CHK2 in human cancer
Craig, A. L., & Hupp, T. R. (2004) · Oncogene · doi:10.1038/sj.onc.1208035 · Cited by 27
“Similar to Chk2, some Mdm2 splice variants are dominant negative over wild-type Mdm2 (Evans et al., 2001), while others have enhanced oncogenicity and are associated with p53-independent tumorigenesis (Fridman et al., 2003; Steinman et al., 2004).”
BackgroundHdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells
Sui, X., Shin, S., Zhang, R., Firozi, P. F., Yang, L., Abbruzzese, J. L., & Reddy, S. A. G. (2009) · Oncogene · doi:10.1038/onc.2008.423 · Cited by 25
“, 1998), and hdm2 splice variants lacking portions of the p53-binding domain and possessing transforming activities were found in human tumors (Sigalas et al., 1996; Fridman et al., 2003; Steinman et al., 2004; Harris, 2005).”
BackgroundJacob, A. G., O'Brien, D., Singh, R. K., Comiskey, D. F., Littleton, R. M., Mohammad, F., Gladman, J. T., Widmann, M. C., Jeyaraj, S. C., Bolinger, C., et al. (2013) · Neoplasia · doi:10.1593/neo.13286 · Cited by 28
“Further, the expression of Mdm2-b (mouse homolog of MDM2-ALT1) under a glial fibrillary acidic protein promoter spontaneously induced the formation of myeloid sarcomas and B cell lymphomas in transgenic mice [46].”
BackgroundUsing Mouse Models to Explore MDM-p53 Signaling in Development, Cell Growth, and Tumorigenesis
Gannon, H., & Jones, S. N. (2012) · Genes & Cancer · doi:10.1177/1947601912455324 · Cited by 27
“These variants were found to promote tumorigenesis in mice, even though these splice-isoforms encoded Mdm2 proteins that lack the p53-binding domain.(84,85) More recent studies using Mdm2 transgenic mice have revealed a role for Mdm2 in DNA break repair and chromosomal damage in cells lacking p53.”
BackgroundSelf-citationStress-Induced Alternative Splice Forms of MDM2 and MDMX Modulate the p53-Pathway in Distinct Ways
Jacob, A. G., Singh, R. K., Comiskey, D. F., Rouhier, M. F., Mohammad, F., Bebee, T. W., & Chandler, D. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104444 · Cited by 25
Zhou, R., Frum, R. A., Deb, S., & Deb, S. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-03-3755 · Cited by 27
“However, recent reports suggest that many of these interactions may be dispensable for MDM2-mediated oncogenesis (20, 21).”
BackgroundGenomic organisation of the human MDM2 oncogene and relationship to its alternatively spliced mRNAs
Liang, H., Atkins, H., Abdel‐Fattah, R., Jones, S. N., & Lunec, J. (2004) · Gene · doi:10.1016/j.gene.2004.05.015 · Cited by 26
Self-citationCrosstalk Between Vitamin D and p53 Signaling in Cancer: An Update
Reichrath, J., Reichrath, S., VOGT, T. M., & Römer, K. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-46227-7_15 · Cited by 27
Gaur, R. K. (2006) · BioTechniques · doi:10.2144/000112165 · Cited by 24
Singh, R. K., Tapia-Santos, A. S., Bebee, T. W., & Chandler, D. S. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.07.017 · Cited by 25
Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1–MDM2–p53 Pathway
Qin, J., Wang, W., & Zhang, R. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.07.005 · Cited by 23
Alternative splicing ofMDM2 mRNA in lung carcinomas and lung cell lines
Weng, M.-W., Lai, J.-C., Hsu, C.-P., Yu, K.-Y., Chen, C., Lin, T.-S., Lai, W., Lee, H., & Ko, J. (2005) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20118 · Cited by 23
“This may explain why some patients containing P53 mutations and overexpression of MDM2 in tumors have a worse prognosis than those whose tumors have only one of these events [Wurl et al., 1998; Steinman et al., 2004].”
BackgroundInfluentialDownregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3
Yang, P., Chen, W., Li, X., Eilers, G., He, Q., Liu, L., Wu, Y., Wu, Y., Yu, W., Fletcher, J. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8999 · Cited by 21
“For example, MDM2-B stimulates the growth of mouse embryo fibroblasts and exerts antiapoptotic effects [19].”
BackgroundHuun, J., Gansmo, L. B., Mannsåker, B., Iversen, G. T., Øvrebø, J. I., Lønning, P. E., & Knappskog, S. (2017) · BMC Cell Biology · doi:10.1186/s12860-017-0134-z · Cited by 23
“In addition MDM2-B seems capable of inducing p53-independent cell growth [28].”
Sánchez‐Aguilera, A., García, J. F., Sánchez‐Beato, M., & Piris, M. A. (2005) · Oncogene · doi:10.1038/sj.onc.1209282 · Cited by 24
“A different report demonstrated that MDM2-B could stimulate the proliferation of mouse embryo fibroblasts (MEF) of different genotypes and had antiapoptotic activity (Steinman et al., 2004).”
BackgroundWeng, M.-W., Hsiao, Y.-M., Chiou, H., Yang, S., Hsieh, Y., Cheng, Y., Yang, C.-H., & Ko, J. (2005) · DNA repair · doi:10.1016/j.dnarep.2004.12.006 · Cited by 22
Bozzi, F., Conca, E., Laurini, E., Posocco, P., Sardo, A. L., Jocollé, G., Sanfilippo, R. G., Gronchi, A., Perrone, F., Tamborini, E., et al. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.107 · Cited by 22
Hinokiflavone Inhibits MDM2 Activity by Targeting the MDM2-MDMX RING Domain
Ilic, V. K., Egorova, O., Tsang, E., Gatto, M., Wen, Y., Zhao, Y., & Sheng, Y. (2022) · Biomolecules · doi:10.3390/biom12050643 · Cited by 21
p53 and MDM2 are involved in the regulation of osteocalcin gene expression
Chen, H., Kolman, K., Lanciloti, N., Nerney, M. P., Hays, E., Robson, C., & Chandar, N. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.02.022 · Cited by 20
“Numb, RB, p300, insulin like growth factor receptor, estrogen receptor, and androgen receptor, involved in different cellular activities such as cell fate determination, differentiation, and signaling [32,33,34,35].”
BackgroundVolk, E. L., Schuster, K., Nemeth, K. M., Fan, L., & Harris, L. C. (2008) · Disease Models & Mechanisms · doi:10.1242/dmm.000992 · Cited by 20
“However, the data presented here are in contrast to those of others describing an oncogenic phenotype for other, similar, MDM2 variants (Fridman et al., 2003; Steinman et al., 2004).”
ResultSF3A1 and pancreatic cancer: new evidence for the association of the spliceosome and cancer
Tian, J., Liu, Y., Zhu, B., Tian, Y., Zhong, R., Chen, W., Lu, X., Zou, L., Shen, N., Qian, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5647 · Cited by 21
“Its over expression reportedly contributes to pancreatic neoplastic transformation [34], and its splicing variants may promote p53-independent cell growth, inhibit apoptosis and contribute to tumorigenesis [35].”
SRSF2 Regulation of MDM2 Reveals Splicing as a Therapeutic Vulnerability of the p53 Pathway
Comiskey, D. F., Montes, M., Khurshid, S., Singh, R. K., & Chandler, D. S. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0541 · Cited by 19
“This in turn results in the stabilization of p53 and subsequent upregulation of 47 pathways involved in apoptosis and cell cycle arrest (6-8).”
BackgroundSplice Variants of MDM2 in Oncogenesis
Rosso, M., Okoro, D. R., & Bargonetti, J. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_14 · Cited by 20
Fan, C., & Wang, X. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1288327 · Cited by 17
What do we need to know and understand about p53 to improve its clinical value?
Salomao, N., Karakostis, K., Hupp, T., Vollrath, F., Vojtesek, B., & Fahraeus, R. (2021) · The Journal of Pathology · doi:10.1002/path.5677 · Cited by 15
“The physiological importance of this feedback loop was tested by generating mice that lack the p53 binding site on theMdm2 promoter [66,67].”
BackgroundMatijašević, Z., Krzywicka-Racka, A., Sluder, G., Gallant, J., & Jones, S. N. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.62 · Cited by 14
Self-citationBi, H., Tian, T., Zhu, L., Zhou, H., Hu, H., Liu, Y., Li, X., Hu, F., Zhao, Y., & Wang, G. (2016) · Scientific Reports · doi:10.1038/srep29869 · Cited by 13
“MDM2 , functioning as an oncogene, is amplified in approximately one-third of all human carcinomas including CRC 24 .”
A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo
Comiskey, D. F., Jacob, A. G., Sanford, B. L., Montes, M., Goodwin, A., Steiner, H. E., Matsa, E., Tapia-Santos, A. S., Bebee, T. W., Grieves, J. L., et al. (2017) · Oncogene · doi:10.1038/onc.2017.282 · Cited by 16
“To appraise the effects of MDM2-ALT1 in mice with fully functional p53, we expressed MDM2-ALT1 in B cells where any p53-associated cell death or apoptosis will not have overt systemic effects such as embryonic lethality (44) or major organ failure.”
InfluentialLama, R., Xu, C., Galster, S. L., Querol-García, J., Portwood, S. M., Mavis, C. K., Ruiz, F. M., Martin, D. L., Wu, J., Giorgi, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.933446 · Cited by 15
“MDM2 splice isoforms MDM2A and MDM2B that lack p53-binding domains promote lymphomagenesis as efficiently as full-length MDM2 (47, 48).”
BackgroundNovel MDM2 splice variants identified from oral squamous cell carcinoma
Sam, K. K., Gan, C. P., Yee, P. S., Chong, C., Lim, K. P., Karen‐Ng, L. P., Chang, W. S., Nathan, S., Rahman, Z. A. A., Ismail, S. M., et al. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.05.016 · Cited by 12
Identification of spliced variants of the proto‐oncogene hdm2 in colorectal cancer
Yu, Z., Zhang, B., Cui, B., Wang, Y., Han, P., & Wang, X. (2011) · Cancer · doi:10.1002/cncr.26330 · Cited by 12
“This alternative splice was identical to that described previously by Evans et al(13) and referred to there as hdm2-B, and has been proven to promote p53-independent cell growth, inhibit apoptosis, and induce tumor formation in transgenic mice.(14) hdm2-B is the most frequently detected hdm2 spliced variant found in h…”
MethodsiRNA-mediated MDM2 inhibition sensitizes human lung cancer A549 cells to radiation
Wanfeng, G., Ahmed, K. M., Hui, Y., Guo, G., & Li, J. J. (2007) · International Journal of Oncology · doi:10.3892/ijo.30.6.1447 · Cited by 12
Islamian, J. P., Mohammadi, M., Baradaran, B., Farajollahi, A., Aghamiri, S. M. R., Jafarabadi, M. A., Karami, H., Monfaredan, A., & Shanehbandi, D. (2016) · Bioimpacts · doi:10.15171/bi.2016.13 · Cited by 11
The role of miRNAs in MDMX‐p53 interplay
Yu, D., Xu, Z., Cheng, X., & Qin, J. (2021) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12428 · Cited by 4
Hu, Z., Zhang, X., Yang, H., Qin, S., Liu, Y., Xiong, W., Yuan, B., Li, L., Yao, W., & Wu, D. (2017) · Oncology Letters · doi:10.3892/ol.2017.7205 · Cited by 4
RING Fingers and Relatives: Determinators of Protein Fate
Lorick, K. L., Tsai, Y. C., Yang, Y., & Weissman, A. M. (2007) · Wiley eBooks · doi:10.1002/9783527619320.ch4 · Cited by 3
Lama, R., Wu, W., Mavis, C. K., Ruiz, F. M., Querol-García, J., Martin, D., Chemler, S. R., Chandra, D., Goodrich, D. W., Hernandez‐Ilizaliturri, F. J., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1462231 · Cited by 3
dos Santos, T. R. M., da Silva, A. C. G., de Carvalho, F. S., Lobón, G. S., Vaz, B. G., Lião, L. M., Menegatti, R., & Valadares, M. C. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.07.004 · Cited by 2
Cooke, S. F., Wright, T. A., Lappin, G., Kyurkchieva, E., Sin, Y. Y., Ling, J., Zorn, A., O’Gorman, B., Banyard, W., Chang, C.-J., et al. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.201029 · Cited by 2
“16,24 Consequently, there remains a major unmet need for truly broad-reaching MDM2/MDMX inhibitors for the treatment of both MDM2/MDMX-dependent TP53 WT and MT cancers.”
IKKalpha mediated NOTCH1 Activation Promotes Tumorigenesis via FOXA2 Suppression
Liu, M. (2012) · Digital Commons-TMC (Texas Medical Center)
Regulation of Alternative Splicing by microRNAs
Gaur, R. K. (2009) · CRC Press eBooks · doi:10.1201/9781420008708.ch14
MEK inhibition in pancreas cancer
Vena, F. (2016) · UCL Discovery (University College London)
Effect of stress during neutron irradiation on the microstructure of type 316 stainless steel
Brager, H. R., Garner, F. A., & Guthrie, G. L. (1976) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
Haupt, Y., & Haupt, S. (2014) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718214290.793498112
(2009) · Disease Models & Mechanisms · doi:10.1242/dmm.002089
Data from Delineation of TMPRSS2-ERG Splice Variants in Prostate Cancer
Hu, Y., Dobi, A., Sreenath, T., Cook, C., Tadase, A. Y., Ravindranath, L., Cullen, J., Furusato, B., Chen, Y., Thangapazham, R. L., et al. (2023) · doi:10.1158/1078-0432.c.6516946.v1
Volk, E. L., Fan, L., Schuster, K., Rehg, J. E., & Harris, L. C. (2023) · doi:10.1158/1541-7786.22519486
Volk, E. L., Fan, L., Schuster, K., Rehg, J. E., & Harris, L. C. (2023) · doi:10.1158/1541-7786.22519486.v1
Implication de la voie p53 dans les syndromes d'insuffisance médullaire
Durand, R. (2020) · theses.fr (ABES) · doi:10.70675/6ccc120bz65f7z4c6czabf5z9bea26651b66
Metadata
- Authors
- Steinman, H. A., Burstein, E., Lengner, C., Gosselin, J., Pihan, G., Duckett, C. S., & Jones, S. N.
- Affiliations
- University of Michigan (US)
- University of Massachusetts Chan Medical School (US)
- Corresponding author
- Jones, Stephen N.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-02
- Volume
- 279
- Issue
- 6
- Pages
- 4877-4886
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2151665323
- Cited by
- 96
- References
- 51
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 3 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 7 · 2016: 8 · 2015: 3 · 2014: 6 · 2013: 6 · 2012: 8
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6077 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship@UMassChan (submittedVersion)
- Funders
- National Cancer Institute (CA 77735)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK032520)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- MDM2, alternative splicing, sarcoma, carcinogenesis, cell growth, apoptosis inhibition, NF-κB RelA, transgenic mice
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Cell Division, Humans, Mice, Transgenic, Molecular Sequence Data, Nuclear Proteins, Proto-Oncogene Proteins, Sarcoma, Experimental, Transfection, Tumor Suppressor Protein p53, Apoptosis, Sequence Homology, Amino Acid, Alternative Splicing, DNA, Complementary, NIH 3T3 Cells, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.